Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
MGC Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.41 |
52 Week High | AU$11.00 |
52 Week Low | AU$0.30 |
Beta | 1.03 |
1 Month Change | 9.33% |
3 Month Change | -13.68% |
1 Year Change | -95.90% |
3 Year Change | -99.32% |
5 Year Change | -98.83% |
Change since IPO | -99.72% |
Recent News & Updates
Recent updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Jun 23MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Mar 09Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)
Oct 08If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns
Feb 21What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?
Dec 30Shareholder Returns
MXC | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -5.7% | 1.1% | 1.5% |
1Y | -95.9% | 44.7% | 11.6% |
Return vs Industry: MXC underperformed the Australian Pharmaceuticals industry which returned 44.7% over the past year.
Return vs Market: MXC underperformed the Australian Market which returned 11.6% over the past year.
Price Volatility
MXC volatility | |
---|---|
MXC Average Weekly Movement | 14.6% |
Pharmaceuticals Industry Average Movement | 10.6% |
Market Average Movement | 8.7% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: MXC's share price has been volatile over the past 3 months.
Volatility Over Time: MXC's weekly volatility has decreased from 39% to 15% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Roby Zomer | https://mgcpharma.com.au |
MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
MGC Pharmaceuticals Limited Fundamentals Summary
MXC fundamental statistics | |
---|---|
Market cap | AU$18.42m |
Earnings (TTM) | -AU$17.02m |
Revenue (TTM) | AU$1.32m |
13.6x
P/S Ratio-1.1x
P/E RatioIs MXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MXC income statement (TTM) | |
---|---|
Revenue | AU$1.32m |
Cost of Revenue | AU$1.20m |
Gross Profit | AU$125.39k |
Other Expenses | AU$17.14m |
Earnings | -AU$17.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.39 |
Gross Margin | 9.47% |
Net Profit Margin | -1,284.89% |
Debt/Equity Ratio | 1,366.5% |
How did MXC perform over the long term?
See historical performance and comparison